MORRISVILLE, N.C. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer of Liquidia , will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare

First dry-powder formulation of treprostinil to meet criteria required for FDA approval Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C. , Nov.

-   Increased adoption of generic Treprostinil Injection by patients, physicians and payers -   Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities -   Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C. , Nov.

MORRISVILLE, N.C. , Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent) owned by United Therapeutics

MORRISVILLE, N.C. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment Conference , which runs from September 13 – 15, 2021.

No Form 483 observations were issued during 5-day inspection MORRISVILLE, N.C. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morrisville, North

MORRISVILLE, N.C. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 (‘793 patent), owned by United Therapeutics Corporation (UTC) and

Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunity Resubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder Improved balance sheet with private placement and increased financial discipline Company to host webcast and conference call today

MORRISVILLE, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021 . The company will host a webcast and conference call at 8:30 a.m.

MORRISVILLE, N.C. , June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension